Inflammation, phospho-p38 MAPK activation, and a reduction in glial cell line-derived neurotrophic factor (GDNF) occur in Parkinson's disease. Microglial activation in the substantia nigra and a tyrosine hydroxylase deficit in the striatum of 3-month-old GDNF heterozygous (GDNF +/− ) mice were previously reported and both were exacerbated by a toxic methamphetamine binge. The current study assessed the effects of minocycline on these methamphetamine-induced effects. Minocycline (45 mg/kg, i.p. × 14 days post-methamphetamine or saline injections) reduced microglial activation and phospho-p38 MAPK in the substantia nigra of salinetreated GDNF +/− mice and in methamphetamine-treated wildtype and GDNF +/− mice. Although minocycline increased tyrosine hydroxylase-immunoreactivity in GDNF +/− mice, it did not attenuate the methamphetamine-induced reduction of tyrosine hydroxylase. The results suggest that neuroinflammation is deleterious to the dopamine system of GDNF +/− mice but is not the primary cause of methamphetamine-induced damage to the dopamine system in either GDNF +/− or wildtype mice.
Introduction
Mice with a partial deletion of glial cell line-derived neurotrophic factor (GDNF) are more vulnerable than wildtype (WT) mice to the neurotoxic effects of the dopaminergic (DAergic) neurotoxin, methamphetamine (METH) (Boger et al., 2007) . Possible antiinflammatory properties of GDNF are suggested by greater microglia activation in the substantia nigra (SN) of 3-month-old GDNF +/− compared to age-matched WT mice. METH exacerbated microgliosis in the SN and tyrosine hydroxylase (TH) depletion in the striatum of GDNF +/− mice; however, the mechanisms are unknown.
High METH doses produce a swift and transient increase in reactive astrogliosis (Sheng et al., 1994; Hebert and O'Callaghan, 2000) and microgliosis in the striatum (Lavoie et al., 2004; Thomas et al., 2004a, b) . Striatal microgliosis was resolved within 1 week in the latter study and within 2 weeks in our recent study (Boger et al., 2007) . Microgliosis in SN was absent 2 days after the METH binge in the study of Thomas et al. (2004b) ; however, it was present 2 weeks after the METH binge in our study, suggesting a delayed microgliotic response without a simultaneous DA cell body loss. In addition to glial activation, METH induces protein phosphorylation cascades that are associated with inflammation and cellular stress (Hebert and O'Callaghan, 2000) . Cellular stressors activate the p38 MAPK pathway which has been implicated in neuronal cell death associated with axotomy and excitotoxicity (Glicksman et al., 1998; Kawasaki et al., 1997) . Further, p38 MAPK mediates pro-inflammatory cytokine production in a variety of cell types (Lee et al., 1994; Chen and Wang, 1999; Hendricks et al., 2008) , including microglia (Bhat et al., 1998) . Inhibition of p38 MAPK activation improves DA neuronal survival both in culture and after neurotransplantation in a rat model of Parkinson's disease (PD; Zawada et al., 2001) . However, to date induction of the p38 MAPK pathway by METH has not been reported.
Minocycline, a tetracycline-related antibiotic, has anti-inflammatory (Tikka and Koistinaho, 2001; Tikka et al., 2001 ) and anti-apoptotic properties (Zhu et al., 2002; Wang et al., 2004) . Minocycline easily crosses the blood-brain barrier and is reported to reduce neurodegeneration in animal models of ischemia (Yrjanheikki et al., 1998 (Yrjanheikki et al., , 1999 , amyotrophic lateral sclerosis (ALS; Zhu et al., 2002; Kriz et al., 2002 ), Huntington's disease (HD; Chen et al., 2000; Wang et al., 2003), and PD (Du et al., 2001; Wu et al., 2002; Quintero et al., 2006) . The treatment potential for minocycline, however, is tempered by additional reports that it can exacerbate brain injury in animal models of PD, HD, and ischemia (Diguet et al., 2004; Yang et al., 2003; Tsuji et al., 2004; Sriram et al., 2006) , as well as ALS symptoms in a clinical trial (Gordon et al., 2007) . Despite the controversy over its positive vs. negative effects, the efficacy and safety of minocycline are being evaluated in clinical trials for PD and HD (Blum et al., 2004; LeWitt and Taylor 2008) .
In the present study, we used a minocycline treatment regimen, demonstrated to be neuroprotective in two different models of Neurobiology of Disease 33 (2009) [459] [460] [461] [462] [463] [464] [465] [466] 
